KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash from Operations (2016 - 2025)

Historic Cash from Operations for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $402.6 million.

  • BeOne Medicines' Cash from Operations rose 11370.45% to $402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $785.4 million, marking a year-over-year increase of 27954.75%. This contributed to the annual value of -$140.6 million for FY2024, which is 8785.0% up from last year.
  • Per BeOne Medicines' latest filing, its Cash from Operations stood at $402.6 million for Q3 2025, which was up 11370.45% from $263.6 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cash from Operations registered a high of $402.6 million during Q3 2025, and its lowest value of -$563.8 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$221.6 million (2023), whereas its average is -$144.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 35036.27% in 2022, then surged by 37576.47% in 2025.
  • Quarter analysis of 5 years shows BeOne Medicines' Cash from Operations stood at $127.1 million in 2021, then plummeted by 350.36% to -$318.2 million in 2022, then soared by 30.34% to -$221.6 million in 2023, then skyrocketed by 133.91% to $75.2 million in 2024, then surged by 435.59% to $402.6 million in 2025.
  • Its last three reported values are $402.6 million in Q3 2025, $263.6 million for Q2 2025, and $44.1 million during Q1 2025.